Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 1;105(9):e3293-e3299.
doi: 10.1210/clinem/dgaa412.

Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment

Iris de Nie  1   2 , Christel J M de Blok  1   2 , Tim M van der Sluis  3 , Ellis Barbé  4 , Garry L S Pigot  2   3 , Chantal M Wiepjes  1   2 , Nienke M Nota  1   2 , Norah M van Mello  2   5 , Noelle E Valkenburg  1 , Judith Huirne  5 , Louis J G Gooren  1   2 , R Jeroen A van Moorselaar  3 , Koen M A Dreijerink  1   2 , Martin den Heijer  1   2
Affiliations

Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment

Iris de Nie et al. J Clin Endocrinol Metab. .

Abstract

Context: Trans women (male sex assigned at birth, female gender identity) mostly use antiandrogens combined with estrogens and can subsequently undergo vaginoplasty including orchiectomy. Because the prostate remains in situ after this procedure, trans women are still at risk for prostate cancer.

Objective: To assess the incidence of prostate cancer in trans women using hormone treatment. The incidence of prostate cancer in trans women using hormone treatment.

Design: In this nationwide retrospective cohort study, data of participants were linked to the Dutch national pathology database and to Statistics Netherlands to obtain data on prostate cancer diagnosis and mortality.

Setting: Gender identity clinic.

Participants: Trans women who visited our clinic between 1972 and 2016 and received hormone treatment were included.

Main outcome measures: Standardized incidence ratios (SIRs) were calculated using the number of observed prostate cancer cases in our cohort and the number of expected cases based on age-specific incidence numbers from the Netherlands Comprehensive Cancer Organization.

Results: The study population consisted of 2281 trans women with a median follow-up time of 14 years (interquartile range 7-24), and a total follow-up time of 37 117 years. Six prostate cancer cases were identified after a median 17 years of hormone treatment. This resulted in a lower prostate cancer risk in trans women than in Dutch reference males (SIR 0.20, 95% confidence interval 0.08-0.42).

Conclusions: Trans women receiving androgen deprivation therapy and estrogens have a substantially lower risk for prostate cancer than the general male population. Our results support the hypothesis that androgen deprivation has a preventive effect on the initiation and development of prostate cancer.

Keywords: androgen deprivation; gender dysphoria; prostate cancer; transgender.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study flowchart.
See this image and copyright information in PMC

References

    1. APA. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association, 2013.
    1. Wiepjes CM, Nota NM, de Blok CJM, et al. . The Amsterdam cohort of gender dysphoria study (1972-2015): trends in prevalence, treatment, and regrets. J Sex Med. 2018;15(4):582-590. - PubMed
    1. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. . Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903. - PubMed
    1. Wierckx K, Van Caenegem E, Schreiner T, et al. . Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11(8):1999-2011. - PubMed
    1. den Heijer M, Bakker A, Gooren L. Long term hormonal treatment for transgender people. BMJ. 2017;359:j5027. - PubMed

Substances